Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics Statistics

Total Valuation

LCTX has a market cap or net worth of $158.36 million. The enterprise value is $121.39 million.

Market Cap	158.36M
Enterprise Value	121.39M

Important Dates

The next estimated earnings date is Friday, November 15, 2024, after market close.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	n/a

Share Statistics

LCTX has 188.84 million shares outstanding. The number of shares has increased by 6.05% in one year.

Shares Outstanding	188.84M
Shares Change (YoY)	+6.05%
Shares Change (QoQ)	+3.23%
Owned by Insiders (%)	0.44%
Owned by Institutions (%)	28.82%
Float	146.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	24.46
Forward PS	13.34
PB Ratio	2.32
P/FCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	19.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.04.

Current Ratio	2.64
Quick Ratio	2.54
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -35.04% and return on invested capital (ROIC) is -19.09%.

Return on Equity (ROE)	-35.04%
Return on Assets (ROA)	-12.86%
Return on Capital (ROIC)	-19.09%
Revenue Per Employee	$82,480
Profits Per Employee	-$322,493
Employee Count	75
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.32% in the last 52 weeks. The beta is 1.28, so LCTX's price volatility has been higher than the market average.

Beta (5Y)	1.28
52-Week Price Change	-28.32%
50-Day Moving Average	0.88
200-Day Moving Average	1.02
Relative Strength Index (RSI)	45.59
Average Volume (20 Days)	451,453

Short Selling Information

The latest short interest is 15.77 million, so 8.35% of the outstanding shares have been sold short.

Short Interest	15.77M
Short Previous Month	15.63M
Short % of Shares Out	8.35%
Short % of Float	10.78%
Short Ratio (days to cover)	35.94

Income Statement

In the last 12 months, LCTX had revenue of $6.19 million and -$24.19 million in losses. Loss per share was -$0.13.

Revenue	6.19M
Gross Profit	7.80M
Operating Income	-22.07M
Pretax Income	-24.19M
Net Income	-24.19M
EBITDA	-21.40M
EBIT	-22.07M
Loss Per Share	-$0.13

Balance Sheet

The company has $38.50 million in cash and $2.95 million in debt, giving a net cash position of $35.55 million or $0.19 per share.

Cash & Cash Equivalents	38.50M
Total Debt	2.95M
Net Cash	35.55M
Net Cash Per Share	$0.19
Equity (Book Value)	66.88M
Book Value Per Share	0.36
Working Capital	25.12M

Cash Flow

In the last 12 months, operating cash flow was -$22.02 million and capital expenditures -$318,000, giving a free cash flow of -$22.33 million.

Operating Cash Flow	-22.02M
Capital Expenditures	-318,000
Free Cash Flow	-22.33M
FCF Per Share	-$0.12

Margins

Gross Margin	126.08%
Operating Margin	-356.69%
Pretax Margin	-391.25%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-361.02%

Dividends & Yields

LCTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-6.05%
Shareholder Yield	-6.05%
Earnings Yield	-15.27%
FCF Yield	-14.10%

Analyst Forecast

The average price target for LCTX is $5.67, which is 576.13% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.67
Price Target Difference	576.13%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	76.94%
EPS Growth Forecast (5Y)	1.28%

Stock Splits

The last stock split was on October 31, 1997. It was a forward split with a ratio of 3:1.

Last Split Date	Oct 31, 1997
Split Type	Forward
Split Ratio	3:1

Scores

LCTX has an Altman Z-Score of -2.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.23
Piotroski F-Score	2